{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:54:39Z","timestamp":1790949279431,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.virol.2024.110375","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T12:21:43Z","timestamp":1735042903000},"page":"110375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Targeting CCR5: A central approach to HIV treatment and cure strategies"],"prefix":"10.1016","volume":"603","author":[{"given":"Yunus","family":"Yukselten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Wishah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110375_bib1","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.3389\/fmicb.2018.02940","article-title":"Gene editing of HIV-1 Co-receptors to prevent and\/or cure virus infection","volume":"9","author":"Allen","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.virol.2024.110375_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.virol.2024.110375_bib3","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1073\/pnas.96.10.5698","article-title":"A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity","volume":"96","author":"Baba","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110375_bib4","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1086\/319755","article-title":"Effects of virologic rebound on CD4 cell counts","volume":"32","author":"Bahrani","year":"2001","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"key":"10.1016\/j.virol.2024.110375_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/frne.2001.0214","article-title":"Chemokines and their receptors in the central nervous system","volume":"22","author":"Bajetto","year":"2001","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.virol.2024.110375_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/14712590802571928","article-title":"Elite control of HIV infection: implications for vaccine design","volume":"9","author":"Baker","year":"2009","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.virol.2024.110375_bib7","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4177::AID-IMMU4177>3.0.CO;2-J","article-title":"Characterization of T cell\u2010expressed chimeric receptors with antibody\u2010type specificity for the CD4 binding site of HIV\u20101 gp120","volume":"28","author":"Bitton","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.virol.2024.110375_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13073-015-0174-y","article-title":"RNA interference approaches for treatment of HIV-1 infection","volume":"7","author":"Bobbin","year":"2015","journal-title":"Genome Med."},{"key":"10.1016\/j.virol.2024.110375_bib9","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1016\/j.ijid.2013.02.020","article-title":"Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection","volume":"17","author":"Bon","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm0297-205","article-title":"Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus","volume":"3","author":"Borrow","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2024.110375_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/v15030789","article-title":"Opportunities for CAR-T cell immunotherapy in HIV cure","volume":"15","author":"Campos-Gonzalez","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110375_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11904-022-00605-1","article-title":"HIV compartmentalization in the CNS and its impact in treatment outcomes and cure strategies","volume":"19","author":"Chan","year":"2022","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.virol.2024.110375_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/mt.2014.32","article-title":"Optimized lentiviral vectors for HIV gene therapy: multiplexed expression of small RNAs and inclusion of MGMT(P140K) drug resistance gene","volume":"22","author":"Chung","year":"2014","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.virol.2024.110375_bib14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41467-022-28130-0","article-title":"Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry","volume":"13","author":"Claireaux","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.virol.2024.110375_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use correlates with disease progression in HIV-1--infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2024.110375_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/15476286.2015.1014759","article-title":"HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs","volume":"12","author":"Daniels","year":"2015","journal-title":"RNA Biol."},{"key":"10.1016\/j.virol.2024.110375_bib17","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2217887120","article-title":"CRISPR editing of CCR5 and HIV-1 facilitates viral elimination in antiretroviral drug-suppressed virus-infected humanized mice","volume":"120","author":"Dash","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2024.110375_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110375_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.femsle.2004.09.040","article-title":"HIV and the CCR5-\u039432 resistance allele","volume":"241","author":"de Silva","year":"2004","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Lett."},{"key":"10.1016\/j.virol.2024.110375_bib20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2024.110375_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110375_bib22","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110375_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","article-title":"Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations","volume":"517","author":"Deng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110375_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15284336.2018.1452842","article-title":"PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection","volume":"19","author":"Dhody","year":"2018","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.virol.2024.110375_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.67","article-title":"Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells","volume":"3","author":"DiGiusto","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.virol.2024.110375_bib26","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110375_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/417095a","article-title":"HIV preferentially infects HIV-specific CD4+ T cells","volume":"417","author":"Douek","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110375_bib28","doi-asserted-by":"crossref","first-page":"33409","DOI":"10.1074\/jbc.M111.279596","article-title":"Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5)","volume":"286","author":"Garcia-Perez","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2024.110375_bib29","series-title":"Advances in Protein Chemistry and Structural Biology","first-page":"123","article-title":"Chapter Five - recent developments in CCR5 regulation for HIV cure","author":"Garg","year":"2021"},{"issue":"Suppl. 1","key":"10.1016\/j.virol.2024.110375_bib30","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/1479-5876-9-S1-S9","article-title":"Clinical use of CCR5 inhibitors in HIV and beyond","volume":"9","author":"Gilliam","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.virol.2024.110375_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.20051970","article-title":"CCR5 deficiency increases risk of symptomatic West Nile virus infection","volume":"203","author":"Glass","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2024.110375_bib32","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44360","article-title":"Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members","volume":"8","author":"Gonzalo-Gil","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.virol.2024.110375_bib33","doi-asserted-by":"crossref","first-page":"E4762","DOI":"10.1073\/pnas.1423228112","article-title":"Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor","volume":"112","author":"Gornalusse","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.virol.2024.110375_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-9-S1-S6","article-title":"Selective transmission of R5 HIV-1 variants: where is the gatekeeper?","volume":"9","author":"Grivel","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.virol.2024.110375_bib35","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/QAD.0000000000003931","article-title":"The EBI2 receptor is coexpressed with CCR5 in CD4 + T cells and boosts HIV-1 R5 replication","volume":"38","author":"Guigues","year":"2024","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.virol.2024.110375_bib126","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick Roy","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110375_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.virol.2024.110375_bib38","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1017\/S0950268819000700","article-title":"Co-receptor tropism and genetic characteristics of the V3 regions in variants of antiretroviral-naive HIV-1 infected subjects","volume":"147","author":"Guo","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.virol.2024.110375_bib39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.virol.2024.110375_bib40","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"The lancet. HIV"},{"key":"10.1016\/j.virol.2024.110375_bib41","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1172\/JCI72992","article-title":"Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9","volume":"124","author":"Gupta","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2024.110375_bib42","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2024.110375_bib43","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.virol.2024.110375_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cells12182237","article-title":"The role and therapeutic targeting of CCR5 in breast cancer","volume":"12","author":"Hamid","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.virol.2024.110375_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01953-21","article-title":"Bryostatin-1 decreases HIV-1 infection and viral production in human primary macrophages","volume":"96","author":"Hany","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0140-6736(85)92144-0","article-title":"Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro","volume":"1","author":"Ho","year":"1985","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.virol.2024.110375_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021563","article-title":"A CRISPR-cas cure for HIV\/AIDS","volume":"24","author":"Hussein","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.virol.2024.110375_bib48","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 delta32\/delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110375_bib49","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1128\/AAC.00086-10","article-title":"Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults","volume":"54","author":"Jacobson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110375_bib50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/652190","article-title":"Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody","volume":"201","author":"Jacobson","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib51","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent advances targeting CCR5 for cancer and its role in immuno-oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2024.110375_bib52","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/0008-5472.CAN-17-0915","article-title":"CCR5 governs DNA damage repair and breast cancer stem cell expansion","volume":"78","author":"Jiao","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2024.110375_bib53","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41598-017-00192-x","article-title":"CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis","volume":"7","author":"Joshi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2024.110375_bib54","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3201\/eid1610.100108","article-title":"Chemokine receptor 5 \u25b332 allele in patients with severe pandemic (H1N1) 2009","volume":"16","author":"Keynan","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-61626-x","article-title":"CRISPR\/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1","volume":"14","author":"Khamaikawin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2024.110375_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109741","article-title":"Antiretrovirals to CCR5 CRISPR\/Cas9 gene editing - a paradigm shift chasing an HIV cure","volume":"255","author":"Khan","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.virol.2024.110375_bib57","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1371\/journal.ppat.0020049","article-title":"CCR5 is essential for NK cell trafficking and host survival following Toxoplasma gondii infection","volume":"2","author":"Khan","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2024.110375_bib58","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1128\/JVI.78.6.2790-2807.2004","article-title":"Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor","volume":"78","author":"Kuhmann","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib59","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41590-019-0406-1","article-title":"CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome","volume":"20","author":"Kulkarni","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.virol.2024.110375_bib60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1172\/JCI80563","article-title":"Hematopoietic stem cell transplantation for HIV cure","volume":"126","author":"Kuritzkes","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2024.110375_bib61","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1016\/j.ddtec.2012.07.011","article-title":"Modeling the allosteric modulation of CCR5 function by Maraviroc","volume":"10","author":"Lagane","year":"2013","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.virol.2024.110375_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e318213c2c0","article-title":"Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5\/CCR2 antagonist, in HIV-1\u2013Infected, treatment-experienced, CCR5 antagonist\u2013naive subjects","volume":"57","author":"Lalezari","year":"2011","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.virol.2024.110375_bib63","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s43856-024-00453-7","article-title":"IFN\u03b1 induces CCR5 in CD4+ T cells of HIV patients causing pathogenic elevation","volume":"4","author":"Le Buanec","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.virol.2024.110375_bib64","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.omtm.2022.01.012","article-title":"CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice","volume":"24","author":"Li","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.virol.2024.110375_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.virol.2024.110375_bib67","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1086\/649426","article-title":"CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission","volume":"201","author":"Lim","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.virol.2024.110375_bib69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/v2020574","article-title":"CCR5: from natural resistance to a new anti-HIV strategy","volume":"2","author":"Lopalco","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110375_bib70","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1128\/JVI.78.16.8654-8662.2004","article-title":"Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine\/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro","volume":"78","author":"Maeda","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"key":"10.1016\/j.virol.2024.110375_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discovery"},{"key":"10.1016\/j.virol.2024.110375_bib73","first-page":"785","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus\u2013infected subjects. Blood","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"The Journal of the American Society of Hematology"},{"key":"10.1016\/j.virol.2024.110375_bib74","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/JVI.02265-08","article-title":"HLA-B57\/B\u22175801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition","volume":"83","author":"Miura","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib75","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","article-title":"Current progress in non-viral RNAi-based delivery strategies to lymphocytes","volume":"25","author":"Mizrahy","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.virol.2024.110375_bib76","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1093\/nar\/gkv469","article-title":"mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5","volume":"43","author":"Mock","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virol.2024.110375_bib77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/088922204322749567","article-title":"The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection","volume":"20","author":"Moore","year":"2004","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.virol.2024.110375_bib78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/COH.0b013e3283223d46","article-title":"A pi\u00e8ce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors","volume":"4","author":"Moore","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2024.110375_bib79","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2334-11-43","article-title":"High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort","volume":"11","author":"Nakanjako","year":"2011","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.virol.2024.110375_bib80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/microorganisms11010221","article-title":"HIV and drug-resistant subtypes","volume":"11","author":"Nastri","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.virol.2024.110375_bib81","volume":"vol. 121","author":"Obrien","year":"2024"},{"key":"10.1016\/j.virol.2024.110375_bib82","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/JVI.73.1.797-800.1999","article-title":"Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy","volume":"73","author":"Ogg","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib83","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1086\/646609","article-title":"Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study","volume":"200","author":"Okulicz","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib84","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/JVI.73.5.4145-4155.1999","article-title":"Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5","volume":"73","author":"Olson","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib85","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1016\/j.cell.2022.09.026","article-title":"Structural basis for Cas9 off-target activity","volume":"185","author":"Pacesa","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.virol.2024.110375_bib86","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1182\/blood-2015-09-672337","article-title":"Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates","volume":"127","author":"Peterson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.virol.2024.110375_bib87","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.drudis.2008.06.008","article-title":"Maintaining the silence: reflections on long-term RNAi","volume":"13","author":"Raemdonck","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.virol.2024.110375_bib88","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1086\/315315","article-title":"CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1","volume":"181","author":"Reynes","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib89","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1742-4690-8-89","article-title":"HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry","volume":"8","author":"Roche","year":"2011","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2024.110375_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1742-4690-10-43","article-title":"A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations","volume":"10","author":"Roche","year":"2013","journal-title":"Retrovirology"},{"key":"10.1016\/j.virol.2024.110375_bib91","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/338255","article-title":"Daily dosing of highly active antiretroviral therapy","volume":"34","author":"Rosenbach","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110375_bib92","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nbt1367","article-title":"Genetic therapies against HIV","volume":"25","author":"Rossi","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.virol.2024.110375_bib93","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/v15010202","article-title":"Development of HIV-resistant CAR T cells by CRISPR\/cas-mediated CAR integration into the CCR5 locus","volume":"15","author":"Rothemejer","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110375_bib94","first-page":"1341","article-title":"Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection","volume":"151","author":"Rottman","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.virol.2024.110375_bib95","first-page":"3","article-title":"C-C motif chemokine receptors in gastric cancer","volume":"8","author":"Ryu","year":"2018","journal-title":"Molecular and clinical oncology"},{"key":"10.1016\/j.virol.2024.110375_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03277-z","article-title":"Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells","author":"S\u00e1ez-Ciri\u00f3n","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.virol.2024.110375_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/v10010008","article-title":"RNA interference therapies for an HIV-1 functional cure","volume":"10","author":"Scarborough","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.virol.2024.110375_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.821190","article-title":"Biallelic, selectable, knock-in targeting of CCR5 via CRISPR-cas9 mediated homology directed repair inhibits HIV-1 replication","volume":"13","author":"Scheller","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110375_bib99","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41434-021-00259-5","article-title":"Automated production of CCR5-negative CD4(+)-T cells in a GMP-compatible, clinical scale for treatment of HIV-positive patients","volume":"28","author":"Schwarze","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.virol.2024.110375_bib100","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.3389\/fimmu.2019.02711","article-title":"CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases","volume":"10","author":"Seif","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110375_bib101","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.3","article-title":"RNAi-mediated CCR5 knockdown provides HIV-1 resistance to memory T cells in humanized BLT mice","volume":"4","author":"Shimizu","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.virol.2024.110375_bib102","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1158\/0008-5472.CAN-14-0612","article-title":"CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines","volume":"74","author":"Sicoli","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2024.110375_bib103","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","article-title":"Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1","volume":"49","author":"Strizki","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2024.110375_bib104","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jso.20984","article-title":"Prognostic significance of expression of CCL5\/RANTES receptors in patients with gastric cancer","volume":"97","author":"Sugasawa","year":"2008","journal-title":"J. Surg. Oncol."},{"issue":"182","key":"10.1016\/j.virol.2024.110375_bib105","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.182.3.1746","article-title":"Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer","author":"Tan","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.virol.2024.110375_bib106","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1126\/science.1241475","article-title":"Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex","volume":"341","author":"Tan","year":"2013","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.virol.2024.110375_bib107","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2024.110375_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2024.110375_bib109","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110375_bib110","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110375_bib111","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1073\/pnas.012519099","article-title":"HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use","volume":"99","author":"Trkola","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110375_bib112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1089\/hum.2011.165","article-title":"Characterization of an HIV-targeted transcriptional gene-silencing RNA in primary cells","volume":"23","author":"Turner","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.virol.2024.110375_bib113","series-title":"The Path that Ends AIDS: UNAIDS Global AIDS Update 2024","author":"UNAIDS","year":"2024"},{"key":"10.1016\/j.virol.2024.110375_bib114","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/0008-5472.CAN-11-3917","article-title":"CCR5 antagonist blocks metastasis of basal breast cancer cells","volume":"72","author":"Velasco-Vel\u00e1zquez","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.virol.2024.110375_bib115","first-page":"467","article-title":"Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection","volume":"96","author":"Walker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.virol.2024.110375_bib116","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"JAK\/STAT signaling pathway affects CCR5 expression in human CD4(+) T cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.virol.2024.110375_bib117","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/aid.2020.0064","article-title":"Anti-HIV activity of standard combined antiretroviral therapy in primary cells is intensified by CCR5-targeting drugs","volume":"36","author":"Weichseldorfer","year":"2020","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.virol.2024.110375_bib118","doi-asserted-by":"crossref","DOI":"10.1097\/COH.0b013e3280142007","article-title":"Resistance to CCR5 antagonists","volume":"2","author":"Westby","year":"2007","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.virol.2024.110375_bib119","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"Westby","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110375_bib120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virol.2004.07.021","article-title":"Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses","volume":"328","author":"Wolinsky","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.virol.2024.110375_bib121","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1021\/jm501772w","article-title":"Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors","volume":"58","author":"Wu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.virol.2024.110375_bib122","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1084\/jem.186.8.1373","article-title":"Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding","volume":"186","author":"Wu","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.virol.2024.110375_bib123","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110375_bib124","first-page":"869","article-title":"Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells","volume":"7","author":"Zi","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.virol.2024.110375_bib125","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","article-title":"The chemokine superfamily revisited","volume":"36","author":"Zlotnik","year":"2012","journal-title":"Immunity"}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224003994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T13:05:02Z","timestamp":1769951102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224003994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":125,"alternative-id":["S0042682224003994"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110375","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CCR5: A central approach to HIV treatment and cure strategies","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110375"}}